


SWISS BIOTECH SUCCESS STORIES

Celebrating and honoring major achievements



- A wholly owned subsidiary of Vir Biotechnology (Nasdaq: VIR) since 2017
- Co-founded in 2004 by Prof. Antonio Lanzavecchia, MD, a renowned immunologist and founding director of the Institute for Research in Biomedicine (IRB) in Bellinzona, and Prof. William J. Rutter, Ph.D., an industry veteran, academic and successful entrepreneur
- A pioneer in the discovery, engineering, and early development of human monoclonal antibodies to fight infectious diseases
- Incubated in its early days within the IRB
- The antibodies discovered and developed by Humabs have made an impact on the infectious disease landscape
- Expected 2023 data readouts from clinical trials evaluating antibodies for flu, hepatitis B and hepatitis D virus infection – all investigational monoclonal antibodies that came out of the work at Humabs BioMed

Leadership Team



From left to right:

Filippo Riva, MBA
SVP, Managing Director

Nadia Passini, PhD
Senior Director, Operations


Davide Corti, PhD
SVP, Antibody Research

Antonio Lanzavecchia, M.D.
Scientific Founder, SVP and Senior Research Fellow



Marketed Products

- Ebanga (ansuvimab-zykl), a monoclonal antibody licensed to Ridgeback Therapeutics, has shown an efficacy of more than 89% in the treatment of Zaire ebolavirus during the 2018-19 Ebola outbreak in the Democratic Republic of Congo. Branded Ebanga®, it is approved by the FDA and recommended by the WHO.
- Xevudy (sotrovimab): a monoclonal antibody therapy developed for adults and pediatric patients (12 years of age and older) who are at high risk for progression to severe COVID-19, including hospitalization or death. Under the brand name Xevudy®, Sotrovimab has obtained emergency authorization, temporary authorization or marketing approval for early treatment of COVID-19, supplying more than 40 countries. Sotrovimab is not authorized in the US.



Investigational Antibody Clinical Stage Pipeline

- VIR-2482: monoclonal antibody for the prevention of influenza A*
- VIR-3434: monoclonal antibody for the treatment of hepatitis B and D

* The development of VIR-2482 is funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50122C00081



Knowledge & Research

The world class scientific team at Humabs has published its scientific discoveries in dozens of prestigious peer-reviewed scientific journals such as Science, Nature and Cell.




Partnerships & Collaborations

Together with Vir, Humabs has numerous collaborations and partnerships ranging from industry such as GSK, to NGOs such as the Bill & Melinda Gates Foundation, to government organizations such as BARDA, the NIH and DARPA.

Award winner 2023



Bellinzona



SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Scientific breakthrough
- ★ Strong impact on society
- ★ Product approval and sustainable revenues

- ★ Important IP, innovative deal-making, acquisition
- ★ Involvement of one or more Swiss citizens
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Swissness: Think global, made in Switzerland